A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults With Malignant Pleural Mesothelioma

Trial Profile

A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults With Malignant Pleural Mesothelioma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs CRS 207 (Primary) ; Cisplatin; Cyclophosphamide; Pemetrexed
  • Indications Mesothelioma
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Aduro BioTech
  • Most Recent Events

    • 28 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 28 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 25 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top